Terbinafine used safely in autoimmune hepatitis for treatment of tinea corporis

BMJ Case Rep. 2021 May 25;14(5):e243143. doi: 10.1136/bcr-2021-243143.

Abstract

Terbinafine is often considered contraindicated in those with liver disease, as one of the known side effects is hepatotoxicity. We report the first case documenting the safe use of oral terbinafine in a 77-year-old woman with stable autoimmune hepatitis presenting with extensive tinea corporis. Precautions were carried out to minimise the risk of worsening hepatotoxicity, including consultation with the patient's hepatologist, limiting terbinafine exposure to less than 6 weeks, monitoring of liver function tests, and patient education. The patient's fungal infection cleared without any signs or symptoms of worsening liver disease. The rash had not recurred 6 months after treatment. When terbinafine must be used in a patient with pre-existing liver disease, we recommend considering a short course of oral terbinafine after consultation with their hepatologist, obtaining baseline liver function tests with consideration of further monitoring during treatment course, and patient education on the signs and symptoms of liver injury.

Keywords: contraindications and precautions; dermatology; drugs: infectious diseases; liver disease.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antifungal Agents / adverse effects
  • Female
  • Hepatitis, Autoimmune* / diagnosis
  • Hepatitis, Autoimmune* / drug therapy
  • Humans
  • Naphthalenes / adverse effects
  • Terbinafine / adverse effects
  • Tinea* / diagnosis
  • Tinea* / drug therapy

Substances

  • Antifungal Agents
  • Naphthalenes
  • Terbinafine